Anticancer agents based on human pancreatic ribonuclease

Technology offer: Anticancer agents based on human pancreatic ribonuclease

Reference: 13 ES 252K 3SRH

Summary: A Catalan research group has developed a new anticancer therapy directed against nuclear RNA based on the engineering of human pancreatic ribonuclease. These ribonucleases are non-genotoxic drugs and it is thought very difficult that they may generate drug resistance phenotype. Their human origin warrants poor or null immunogenicity in clinical uses. License agreement or a technology development agreement with companies is sought.

For more information click here.

Technologické nabídky a poptávky zpracovává BIC Plzeň, partner sítě Enterprise Europe Network.